anti-CD28 monoclonal antibody TGN1412
DISEASE INTERVENTION COMPARISON RESULTS
N Engl J Med. 2006 Sep 7;355(10):1018-28. Epub 2006 Aug 14 Descriptive
IN systemic inflammatory response, cytokine storm, anti-CD28 antibody The Use of
anti-CD28 monoclonal antibody TGN1412
As Treatment, Acute
Is worse Than
no treatment
To directly stimulate T cells and improve immune response: the drug causes multiple cytokine-release leading to severe disease in all tested patients. That can improve our understanding of systemic inflammatory response.